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It is estimated that around 30% of all malignancies
are caused by a “high-risk” genetic predisposition [1].
This estimation is based on an evaluation of
occurrence of disease among monozygotic twins. If
one of them is affected with prostate (PC) or breast
cancer (BC), then the probability of occurrence of this
disease in the second sibling is 40% for PC and 30%
for BC [2]. The concordance among monozygotic twins
is even higher when occurrence of malignancies
regardless of the site of origin is taken into consideration
(e.g. breast cancer in one individual, stomach cancer
in the sibling).
Genetic susceptibility to cancer can be divided into
monogenic and polygenic predisposition.
M Mo on no og ge en ni ic c   p pr re ed di is sp po os si it ti io on n   t to o   c ca an nc ce er r
Such diseases are caused by constitutional mutations
of single genes, present in all cells of the body. DNA
mutations can be detected in all malignancies. In the
majority of cases somatic mutations are identified –
changes which are present in malignant tissue only. To
date, among hereditary causes of malignancies, the most
frequently diagnosed background detected in routine
molecular testing of the patients is monogenic
predisposition with autosomal dominant type of
inheritance. Each individual has two copies (alleles) of
the gene responsible for a particular feature or disease,
in the same locus on homologous chromosomes. One
copy is inherited from the mother, the second one from
the father. According to autosomal dominant type of
inheritance the presence of inborn mutation in a single
copy of the gene leads to disorder [3]. This is true in the
case of proto-oncogenes, e.g. mutations in RET
oncogene predispose to MEN2 syndrome. In the
majority of cases, malignancies are caused by mutations
of the tumour suppressor genes such as p53, or DNA
repair genes such as MSH2, which show a recessive
pattern at the molecular level. Carriers of these
mutations develop cancer due to somatic inactivation
of the second allele (most frequently deletion) during
their lifetime [4-8].
Pedigrees of monogenic diseases with autosomal
dominant inheritance are characterised by occurrence
of the disorder in all generations (vertical transmission),
among men and women, among almost 50% of the
relatives [9, 10].
The pedigree of a family with autosomal dominant
disease is presented in Figure 1.
In this particular family cancers occur at a younger
age in each subsequent generation (so-called anticipation).
Autosomal dominant inheritance does not show
characteristic pedigree features in cases of:
• germline (present in sex cells) mutations arising “de
novo” – disease absent among ancestors and
siblings of the proband (individuals undergoing
genetic counselling); subsequent generations can be
affected – Figure 2;
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• mosaic mutation present only in some of the tissues;
such alterations arise in the fetus “de novo” during
pregnancy; single individuals in the family are
affected; mutation can be inherited only if it is present
in sex cells;
• “low penetrance” mutations; penetrance is defined
as the proportion of carriers of mutation who
develop cancer; in strong cancer familial
aggregations it reaches 80-90%, but in cases with
low penetrance mutations it is much lower, and thus
single individuals only are affected [11-15]; an
example is presented in Figure 3;
• mutations predisposing to disease occurring among
one gender only, e.g. mutations of the BRCA1 gene
are detected among both males and females, but
only women develop ovarian cancer;
• small families with low numbers of relatives.
Evaluation of the pedigree and clinical data of
families with aggregations of cancers should exclude
phenocopies (accidental malignancy not related to
mutation responsible for the aggregation of malignant
tumours) [16-18]. Figure 4 shows an example of 
a family with 4 breast cancers caused by BRCA1
mutation and one breast cancer in a woman without
BRCA1 mutation. 
P Po ol ly yg ge en ni ic c   p pr re ed di is sp po os si it ti io on n   t to o   c ca an nc ce er r
In polygenic type of inheritance single individuals
are usually affected.
As the results of the studies performed in our centre
panels of DNA mutations/polymorphisms, which
increase the risk of malignancies, were identified in over
90% of unselected breast cancers (96% of cases with
BC diagnosed over 50, 99% of lobular cancer cases –
Tables 1-3), 89% of colorectal cancers, 72% of
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malignant melanomas, 36% of ovarian and 27.5% of
prostate cancers [19]. DNA alterations associated with
“moderate” risk may have a significant clinical impact.
Associations of “moderate risk” mutations and
polymorphisms of many genes and additional influence
of environmental factors can significantly increase the
risk of cancer development in individuals carrying these
alterations. Accumulation (linear association) of the
DNA alterations can be identified when the total risk of
cancer is the sum of risks of single DNA alterations, e.g.
total risk of cancer development increased twofold in
compound carriers of two mutations in genes A and B 
(both mutations associated with 50% increased cancer
risk). In other cases a non-linear association
(interaction) can be diagnosed (e.g. total risk increased
fivefold in compound carriers of the previously
mentioned mutations of genes A and B [20]).
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